Rheumatology

A new study lends insights into the prevalence of lung abnormalities in patients with newly diagnosed cases of rheumatoid arthritis (RA).

In pediatric patients with frequently relapsing nephrotic syndrome (FRNS), the therapy was well tolerated, but did not lead to significant changes in disease course.

The new study, based on an analysis of existing literature and a replication cohort, helps clarify the role of a variant in microRNA-146a.

People who suffered trauma as a child appear to be at a higher risk of fibromyalgia, although it is unclear exactly why.

German Hernandez, MD, FASN, FACP, and Ellen Ginzler, MD, MPH, discuss barriers to treatment access in lupus nephritis, and address future directions and unmet needs of the disease.

Patients with axial spondyloarthritis waited the longest, according to new research.

German Hernandez, MD, FASN, FACP, and Ellen Ginzler, MD, MPH, provide insight into the FDA approved therapies for lupus nephritis, belimumab and voclosporin, including an overview of clinical evidence, mechanism of action, and patient selection.

Rheumatology and nephrology experts provide an overview of the pharmacologic treatment options in lupus nephritis and discuss recent FDA approved therapies belimumab and voclosporin.

Results from the FUTURE 5 study show that more than 80% of patients had no radiographic progression of psoriatic arthritis, regardless of dose cohort or whether a loading dose was used.

Ellen Ginzler, MD, MPH, and German Hernandez, MD, FASN, FACP, discuss key drivers of healthcare utilization, progression of patients to end stage renal disease, and goals of treatment for lupus nephritis.

More than three-quarters of patients with rheumatic diseases quarantined and kept social distance during the pandemic, according to a new global survey.

Rheumatology and nephrology experts discuss monitoring of patients, renal flares, and consequences of progression in lupus nephritis.

Ellen Ginzler, MD, MPH, and German Hernandez, MD, FASN, FACP, provide insight into the clinical presentation of patients with lupus nephritis, the progression of systemic lupus erythematosus to lupus nephritis, and the prevalence of this rare disease.

Rheumatologist Ellen Ginzler, MD, MPH, and nephrologist German Hernandez, MD, FASN, FACP, provide an overview of systemic lupus erythematosus and lupus nephritis.

A new report finds roughly three-quarters of patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis used painkillers, although biologics appear to curb the need for nonsteroidal anti-inflammatory drugs, in particular.

The latest news in rheumatology includes the need for robust vaccinations in juvenile idiopathic arthritis; new findings about rheumatoid arthritis (RA) and type 2 diabetes; and quality of life in systemic lupus erythematosus.

When a New Zealand health care network switched to telehealth visits, its rheumatology patients had more health care interactions, but they had fewer changes in care and were less likely to be categorized as having active disease.

Patients who were tumor necrosis factor inhibitor naive generally had better responses to secukinumab compared with those who were inadequate responders—but both groups benefited

In this retrospective cohort study of patients with newly diagnosed psoriatic arthritis, the authors examine the association of treatment selection and costs with physician specialty.

Treatment options for patients with these rare diseases have expanded in recent years, but rheumatologists may have limited experience with systemic vasculitis.

No clinical or genetic markers were found to be predictive of psoriatic arthritis in patients with psoriasis, but one laboratory marker was identified.

A new review shows secukinumab continued to have a strong safety profile after 6 years on the market.

A systematic review found significant evidence supporting self-management interventions for inflammatory arthritis, but also found it was difficult to draw conclusions about specific types of programs.

The latest news in the rheumatology space revealed potential biomarkers for differentiating psoriatic arthritis (PsA) from rheumatoid arthritis (RA), as well as other rheumatology news reported across MJH Life Sciences™.

Clinical trials and postmarketing surveillance suggest secukinumab has a favorable safety profile and low rates of discontinuation. A new study evaluated those metrics in a real-world setting in axial spondyloarthritis (AxSpA) and psoriatic arthritis (PsA).